• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bon Natural Life Limited Announces Pricing of $12 Million Best Efforts Offering

    3/17/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email

    XI'AN, China, March 17, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has priced a best efforts offering of units as described below for aggregate gross proceeds to the Company of $12 million, before deducting placement agent fees and other estimated expenses payable by the Company.

    The offering of ordinary units (or pre-funded units in lieu of such ordinary units) comprised of 8,333,332 shares of the Company's Class A ordinary shares (or pre-funded warrants in lieu of Class A ordinary shares for the pre-funded units), Series A Warrants to purchase one Class A ordinary shares at an exercise price of $1.44 per share (the "Series A Warrants") and Series B Warrants to purchase Class A ordinary shares at an exercise price of $2.16 per share (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The pre-funded warrant will be exercisable immediately upon issuance and will expire when exercised in full. The Warrants will be immediately exercisable upon issuance and will expire on the three year anniversary of their initial exercise date.

    The purchase price of each ordinary unit will be $1.44, and the purchase price of each pre-funded unit will be equal to such price minus $0.001.

    The Company intends to use the net proceeds from this offering for sales network expansion, research and development, production capacity expansion, and working capital and other general corporate purposes. The offering is expected to close on or about March 18, 2025, subject to satisfaction of customary closing conditions.

    Univest Securities, LLC is acting as sole placement agent for the offering.

    The securities described above are being offered by the Company pursuant to a registration statement on Form F-1 (File No. 333-283333), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained, when available, by contacting Univest Securities, LLC at [email protected], or by calling +1 (212) 343-8888.

    About Bon Natural Life Limited

    BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

    Forward-Looking Statements

    Certain statements in this announcement are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Cindy Liu | IR

    Email: [email protected]



    Primary Logo

    Get the next $BON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

    XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agreement (the "Agreement") with Tigerbone Group Limited ("Tigerbone Group").  As part of this strategic initiative, the parties also announced plans to establish the "BON Cooperation and Development Committee," which will serve as a central platform to advance collaboration in traditional Chinese medicine and life sciences through resource sharing and complementary strengths. Pursuant to the Agreement, an

    3/31/26 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

    XI'AN, China, Feb. 19, 2026 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent flexible electronics, creating a next-generation skin care solution designed to be non-invasive, painless, and suitable for at-home use. Serving as the core na

    2/19/26 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

    XI'AN, China, Feb. 17, 2026 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot"). The Joint Laboratory will focus on the research and development of bio-manufactured natural activ

    2/17/26 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    SEC Filings

    View All

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    3/19/26 6:03:08 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    2/17/26 9:00:13 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    12/10/25 6:15:05 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    Bon Natural Life Limited Announces Change to Board Composition

    XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

    6/30/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Financials

    Live finance-specific insights

    View All

    Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

    Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

    2/7/23 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

    7/28/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

    1/28/22 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care